Navigation Links
Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe
Date:8/28/2011

5-mg dose is well tolerated, the dose may be increased to 10 mg once daily.

IMPORTANT SAFETY INFORMATION

VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product.

Angioedema of the face, lips, tongue and/or larynx have been reported with VESIcare. In some cases angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, VESIcare should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.

VESIcare should be administered with caution to patients with bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal or hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended.

In placebo-controlled studies, the most common adverse events reported by patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and dyspepsia (1.4%, 3.9%, 1.0%) with VESIcare 5 mg, 10 mg, and placebo, respectively.

The overall rate of serious adverse events was 2%. For the 10-mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction, and one intestinal obstruction). For the 5-mg dose, one case of angioneurotic edema was reported.

For more information on VESIcare, please visit our website at: http://www.astellas.us/docs/vesicare.pdf

http://www.astellas.c
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 19, 2014 ... ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition ... 2014-2018" report to their offering. ... involves the study of chromosomes using molecular ... of genes and chromosomes. It plays a ...
(Date:9/18/2014)...  Low T Center endorses the recommendations of ... Hyattsville, Maryland earlier this week. The FDA ... population for testosterone therapy (TRT), as well as ... recent claims from studies that TRT affects cardiovascular ... do not provide convincing evidence that TRT is ...
(Date:9/18/2014)... KANSAS CITY, Kan. , Sept. 18, 2014 ... ), a pet therapeutics company focused on licensing, ... animals, today announced the full exercise of the ... common stock in connection with the company,s previously ... stock.  All of the shares are being offered ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... VIEW, Calif., Dec. 21, 2010 MAP Pharmaceuticals, Inc. (Nasdaq: ... ™ open-label safety trial.  The Company has now completed ... (NDA) for LEVADEX and plans to submit an NDA in ... inhaled migraine therapy that has completed Phase 3 clinical development ...
... -- China Botanic Pharmaceutical Inc. (AMEX: CBP ... and distributor of botanical products, bio-pharmaceuticals and traditional Chinese ... considerable progress in its efforts to comply with the ... 404") for fiscal year 2010. As announced ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3China Botanic Announces Progress on its SOX 404 Compliance Program 2China Botanic Announces Progress on its SOX 404 Compliance Program 3
(Date:9/19/2014)... September 19, 2014 September 1, 2014 ... will introduce its state-of-the-art, fiber based, Smart Private Network ... implementation begins in Tahlequah, Oklahoma, which is the capital ... connecting facilities within the Tahlequah area for the remainder ... educational institutions within the fourteen counties of the Cherokee ...
(Date:9/19/2014)... 19, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Potassium Chloride . , ... recalled one lot of Potassium Chloride Injection 10mEq ... cartons. Potassium Chloride, administered intravenously, is used to treat potassium ... on a labeling error on the shipping cartons in a ...
(Date:9/19/2014)... 2014 Mount Pleasant Retirement Village ... Health and Well-Being Coach Christi Hall to campus. , Hall’s ... brain tumors and gaining weight as a result of years ... and learning about nutrition. One year later she had lost ... her strength, endurance and cardio. , After joining the YMCA ...
(Date:9/19/2014)... Final Cut Pro X plugin and effects manufacturer, ... template for Apple's Final Cut Pro X . , ... FCPX users to create a professional themed video with ease ... Pixel Film Studios, "With 48 camera options and On-Screen controls, ... Theme." , Float features all of the tools needed ...
(Date:9/19/2014)... Washington, D.C. (PRWEB) September 19, 2014 ... in Madison County Circuit Court (case 14-L-1175), following a ... Carole Owen is suing DePuy Orthopaedics Inc. and ... product was defective. Flood Law Group, a nationally known ... and has been following developments in litigation involving defective ...
Breaking Medicine News(10 mins):Health News:The Cherokee Nation and RBSC sign a “Memorandum of Agreement” That Brings Smart Connect to the Cherokee Nation 2Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Pixel Film Studios Releases Float Theme for Final Cut Pro X Users 2Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2
... released today by the Association for Psychological Science: , , ... 65; in 2000 that number had jumped to 12.6 percent; and ... in that category. , , Cognitive decline was long ... seen a surge of interest in activities and products touted to ...
... Arcadia Resources, Inc. (NYSE Amex: KAD ... and pharmacy services under the Arcadia HealthCare(SM) brand, has ... Co., as Vice President of DailyMed(TM) Pharmacy Operations , ... the Indianapolis pharmacy operations, manage system integration within DailyMed ...
... Region recognizes immediate, ... ... Center and CHRISTUS St. Vincent Medical Group in Santa Fe, New Mexico, through teamwork, focused ... in nine months. CHRISTUS Health began managing CHRISTUS St. Vincent in April 2008 and ...
... health communications company StayWell Custom Communications (SCC), a division ... Grocer magazine to publish the white paper ... the Economy" to spotlight the retail sector,s growing need ... , , The white paper is a ...
... to include " Oncology Therapeutic ... , , - Center will train pharmacists to specialize in ... 23 Medco Health Solutions, Inc. (NYSE: MHS ), joined ... at AllPoints at Anson will house the Medco Therapeutic Resource Center(R) ...
... diagnostics market is poised for expansion with segments such ... potential. Heightened efforts to generate awareness about diabetes and ... development. For instance, limited awareness about HbA1C tests is ... curtailed with more education about the test. , ...
Cached Medicine News:Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 2Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 2Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 4Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 3Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 2Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 3Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 2Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: